Matthew Angel
Founder presso Exacis Biotherapeutics, Inc.
Patrimonio netto: 75 894 $ in data 29/02/2024
Profilo
Matthew Angel founded Factor Bioscience, Inc., Novellus LLC and Exacis Biotherapeutics, Inc. Presently, Dr. Angel is Director & Chief Scientific Officer at Exacis Biotherapeutics, Inc.
In the past he held the position of Chairman, President & Chief Executive Officer for Factor Bioscience, Inc., President & Chief Executive Officer for Eterna Therapeutics, Inc. and Chief Science Officer at Novellus LLC (a subsidiary of Eterna Therapeutics, Inc.) and President, Chief Executive Officer & Director at Eterna Therapeutics, Inc. and Chief Science Officer at Novellus LLC (a subsidiary of Eterna Therapeutics, Inc.).
He received a doctorate from Massachusetts Institute of Technology and an undergraduate degree from Princeton University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
ETERNA THERAPEUTICS INC.
0.90% | 26/04/2023 | 48 650 ( 0.90% ) | 75 894 $ | 29/02/2024 |
Posizioni attive di Matthew Angel
Società | Posizione | Inizio |
---|---|---|
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Founder | 01/01/2020 |
Precedenti posizioni note di Matthew Angel
Società | Posizione | Fine |
---|---|---|
ETERNA THERAPEUTICS INC. | Chief Executive Officer | 31/12/2023 |
ETERNA THERAPEUTICS INC. | Chief Executive Officer | 04/08/2023 |
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/01/2022 |
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Founder | 01/07/2021 |
Formazione di Matthew Angel
Massachusetts Institute of Technology | Doctorate Degree |
Princeton University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Health Technology |
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA. | Commercial Services |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Health Services |
Eterna Therapeutics, Inc. |